Search Results - "Vynnychenko, I"

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study by Ferris, R.L., Haddad, R., Even, C., Tahara, M., Dvorkin, M., Ciuleanu, T.E., Clement, P.M., Mesia, R., Kutukova, S., Zholudeva, L., Daste, A., Caballero-Daroqui, J., Keam, B., Vynnychenko, I., Lafond, C., Shetty, J., Mann, H., Fan, J., Wildsmith, S., Morsli, N., Fayette, J., Licitra, L.

“…Targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) axis has demonstrated clinical benefit in recurrent/metastatic head…”
Get full text

FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma by Sahin, U., Türeci, Ö., Manikhas, G., Lordick, F., Rusyn, A., Vynnychenko, I., Dudov, A., Bazin, I., Bondarenko, I., Melichar, B., Dhaene, K., Wiechen, K., Huber, C., Maurus, D., Arozullah, A., Park, J.W., Schuler, M., Al-Batran, S.-E.

“…Claudin 18.2 (CLDN18.2) is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed…”
Get full text

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study by Psyrri, A., Fayette, J., Harrington, K., Gillison, M., Ahn, M.-J., Takahashi, S., Weiss, J., Machiels, J.-P., Baxi, S., Vasilyev, A., Karpenko, A., Dvorkin, M., Hsieh, C.-Y., Thungappa, S.C., Segura, P.P., Vynnychenko, I., Haddad, R., Kasper, S., Mauz, P.-S., Baker, V., He, P., Evans, B., Wildsmith, S., Olsson, R.F., Yovine, A., Kurland, J.F., Morsli, N., Seiwert, T.Y.

“…Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis. The phase III KESTREL study evaluated the…”
Get full text

Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study by Bondarenko, I., Juan-Vidal, O., Pajkos, G., Kryzhanivska, A., Pápai Székely, Z., Vicente, D., Vynnychenko, I.O., Jones, S., Wang, Y., Jiang, H., Reinmuth, N.

Get full text

The role of PIK3CA mutations in the development of breast cancer (a literature review) by Pryvalova, A. O., Vynnychenko, I. O., Harbuzova, V. Yu, Vynnychenko, O. I., Moskalenko, Yu. V.

“…Today, breast cancer occupies a leading position in the structure of morbidity and mortality among women in Ukraineand and throughout the world. Late diagnosis…”
Get full text

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review) by Smorodska, O.M., Moskalenko, Yu.V., Vynnychenko, I.O., Vynnychenko, O.I., Kostuchenko, V.V.

“…Tumor molecular profiling in patients with non-small cell lung cancer (NSCLC) is used to identify driver mutations, which lead to premature carcinogenesis in…”
Get full text

Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study by Pirker, R, Pereira, J.R, Szczesna, A, von Pawel, J, Krzakowski, M, Ramlau, R, Vynnychenko, I, Park, K, Eberhardt, W.E.E, de Marinis, F, Heeger, S, Goddemeier, T, O’Byrne, K.J, Gatzemeier, U

“…Abstract The FLEX study demonstrated that the addition of cetuximab to chemotherapy significantly improved overall survival in the first-line treatment of…”
Get full text

HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin by Rugo, H, Barve, A, Waller, C, Bronchud, M.H, Herson, J, Yuan, J, Manikhas, A, Bondarenko, I, Mukhametshina, G, Nemsadze, G, Parra, J, Abesamis Tiambeng, M.L, Baramidze, K, Akewanlop, C, Vynnychenko, I, Sriuranpong, V, Mamillapalli, G, Ray, S, Yanez Ruiz, E.P, Pennella, E

Get full text

ANALYSIS OF THE INCIDENCE RATE OF COLORECTAL CANCER AMONG RESIDENTS OF THE SUMY REGION by Kostiuchenko, V.V., Moskalenko, Y.V., Tarasenko, S.V., Vynnychenko, O.I., Shevchenko, V.V., Vynnychenko, I.O.

“…Before the middle of the 20th century, colorectal cancer (CRC) was a fairly rare disease. A significant increase in the prevalence of this pathology began…”
Get full text

P-195 PREVENTION OF EARLY GASTRIC EMPTYING AND LATE DUODENO-GASTRO-OESOPHAGEAL REFLUX AFTER OESOPHAGOGASTROSTOMY: IS THERE ONE SOLUTION? by Vynnychenko, O., Vynnychenko, I.

Get full text

P-195PREVENTION OF EARLY GASTRIC EMPTYING AND LATE DUODENO-GASTRO-OESOPHAGEAL REFLUX AFTER OESOPHAGOGASTROSTOMY: IS THERE ONE SOLUTION? by Vynnychenko, Oleksandr, Vynnychenko, I.

“…Objectives: Controversy exists about the need for pyloric drainage following oesophageal replacement with gastric tube after oesophagectomy for carcinoma of…”
Get full text

1665PDPreliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study by Bondarenko, I, Juan-Vidal, O, Pajkos, G, Kryzhanivska, A, Pápai Székely, Z, Vicente, D, Vynnychenko, I O, Jones, S, Wang, Y, Jiang, H, Reinmuth, N

Get full text

Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma by Schuler, M., Al-Batran, S.-E., Zvirbule, Z., Manikhas, G., Lordick, F., Rusyn, A., Vinnyk, Y., Vynnychenko, I., Fadeeva, N., Nechaeva, M., Dudov, A., Gotovkin, E., Pecheniy, A., Bazin, I., Bondarenko, I., Melichar, B., Huber, C., Türeci, Ö, Sahin, U.

Get full text

220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer by Lordick, F., Schuler, M., Al-Batran, S.-E., Zvirbule, Z., Manikhas, G., Rusyn, A., Vinnyk, Y., Vynnychenko, I., Fadeeva, N., Nechaeva, M., Dudov, A., Gotovkin, E., Pecheniy, A., Bazin, I., Bondarenko, I., Melichar, B., Huber, C., Sahin, U., Tu¨ reci, O.

Get full text

220O Claudin 18.2 – a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer by Lordick, F., Schuler, M., Al-Batran, S-E., Zvirbule, Z., Manikhas, G., Rusyn, A., Vinnyk, Y., Vynnychenko, I., Fadeeva, N., Nechaeva, M., Dudov, A., Gotovkin, E., Pecheniy, A., Bazin, I., Bondarenko, I., Melichar, B., Huber, C., Sahin, U., Türeci, Ö.

Get full text

Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab by Rugo, H., Barve, A., Waller, C.F., Bronchud, M., Herson, J., Yuan, J., Manikhas, A., Bondarenko, I., Mukhametshina, G., Nemsadze, G., Parra, J.D., Abesamis-Tiambeng, M.L.T., Baramidze, K., Akewanlop, C., Vynnychenko, I., Sriuranpong, V., Mamillapalli, G., Ray, S., Ruiz, E.P. Yanez, Pennella, E.

Get full text

255 - HERITAGE: a phase III safety and efficacy trial of the proposed trastuzumab biosimilar Myl-1401O versus herceptin by Rugo, H., Barve, A., Waller, C., Bronchud, M.H., Herson, J., Yuan, J., Manikhas, A., Bondarenko, I., Mukhametshina, G., Nemsadze, G., Parra, J., Abesamis Tiambeng, M.L., Baramidze, K., Akewanlop, C., Vynnychenko, I., Sriuranpong, V., Mamillapalli, G., Ray, S., Yanez Ruiz, E.P., Pennella, E.

Get full text

Non Inferiority Analysis of Multicenter Phase III Comparing Cisplatin/S-1 (CS) with Cisplatin/5-Fu (CF) as First-Line Therapy in Patients with advanced Gastric Cancer (FLAGS): Methodology and Results by Ajani, J.A., Pantigoso, W. Rodriguez, Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V.A., Vynnychenko, I., Lang, I., Falcon, S.

Get full text

668PD - Non Inferiority Analysis of Multicenter Phase III Comparing Cisplatin/S-1 (CS) with Cisplatin/5-Fu (CF) as First-Line Therapy in Patients with advanced Gastric Cancer (FLAGS): Methodology and Results by Ajani, J.A., Pantigoso, W. Rodriguez, Bodoky, G., Moiseyenko, V., Lichinitser, M., Gorbunova, V.A., Vynnychenko, I., Lang, I., Falcon, S.

“…S-1, a new generation of oral fluoropyrimidine, is active against Advanced Gastric Cancer (AGC). The primary analysis of FLAGS (JCO 2010; vol.28 p 1547-53) did…”
Get full text

Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer by Socinski, M. A., Bondarenko, I. N., Karaseva, N. A., Makhson, A., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Berk, G. I., Iglesias, J. L.

“…Abstract only…”
Get full text